VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [ChIP-Seq]

The transcriptional activity of the TEAD4 trascription factor requires co-activators. In this study we found that the expression of the TEAD coactivator VGLL1 is repressed in estrogen receptor positive breast cancer but upon resistance to endocrine threapies VGLL1 is expressed to high levels. To elucidate the importance of the coactivator VGLL1 in breast cancer cells resistant to endocrine therapies and to identify the VGLL1 target genes, we performed ChIP-seq for VGLL1 in MCF7 breast cancer cells resistant to fulvestrant (FULVR) and ChiP-seq for TEAD4 in FULVR cells and the isogenic MCF7 cells. Overall design: Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) for VGLL1 in the MCF7 cell line resistant to fulvestrant (FULVR) (3 replicates), ChIP-seq for TEAD4 in FULVR cells (2 replicates), ChIP-seq for TEAD4 in the parental cell line MCF7 (2 replicates). ChIP-seq samples were also sequenced together with the input controls in MCF7 and FULVR cell lines